Susan Dexter insider trades
Open-market stock purchases and sales by Susan Dexter, Director at Sonnet BioTherapeutics Holdings, Inc, from SEC Form 4 filings since Jul 2, 2020.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +80%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Dec 2, 2025 | SONN Sonnet BioTherapeutics Holdings, Inc | Sold (not open market) | — |
Companies traded
- SONN Sonnet BioTherapeutics Holdings, Inc: 1 buy, last Dec 2, 2025